You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A chimeric protein for the selective expansion of regulatory T cells

    SBC: SAHANE BIOTECH INC            Topic: NIAID

    DESCRIPTION provided by applicant Type diabetes T D is a chronic disease caused by the autoimmune destruction of the insulin producing beta cells in the pancreas Current treatment options for T D are severely limited All patients diagnosed with T DM are placed on life long insulin therapy and the current standard of care for adult patients with T DM is intensive diabetes therapy to avoid ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A digital brain-gut therapy platform for enhanced management of Irritable Bowel Syndrome

    SBC: METAME HEALTH,INC            Topic: R

    Project Summary Abstract Irritable Bowel Syndrome IBS is a chronic and costly digestive condition characterized by abdominal pain and altered bowel habits diarrhea constipation or mixed type IBS is a disorder of brain gut dysregulation including the amplification of normal gut signals at the level of the brain Yet most medical therapies for IBS to date have focused on symptom management and dietar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced Multi-Modal Wearable Sensing for the Prediction of Pre-Term Labor

    SBC: Sonica LLC            Topic: NICHD

    Preterm birthPTBdelivery prior toweeks gestational ageaccounts forof all births and remains the leading cause of neonatal deathThe majority of PTB is preceded by spontaneous preterm laborPTLCurrentlythere is a major unmet need for methods to identify women at risk of PTL and provide an early warning system for potential interventionhome uterine monitoringHUMis one approach that has shown some prom ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Algorithm to Identify Patients at Risk of Medication-Related Hospitalization

    SBC: L. KRENK, INC.            Topic: R

    The long range goal of this fast track research application is to improve healthcare quality and reduce healthcare costs nationwide among those at risk for medication related hospitalizationThe specific objective of this proposed research is to develop an algorithm that uses existing electronic health information to efficiently identify patients at risk of medication related hospitalization so tha ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Aminomethyl benzamides as novel anti Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Aminopiperidines as novel anti influenza agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Influenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A mobile app to reduce treatment-related financial burden for cancer patients

    SBC: Vivor, Llc            Topic: NCI

    There is a fundamental knowledge gap in how to immediately reduce cancer patientsandapos treatment related financial burden Cancer patients pay more out of pocket for their care than those with other chronic illnesses Half of all elderly cancer patients have high treatment related out of pocket financial burden This financial burden has well defined harmful effects even among insured cancer pa ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel, Microscale, Distributable Sensor Technology for Ionizing Radiation

    SBC: CFD RESEARCH CORPORATION            Topic: DTRA14B004

    Terrorist use of radioactive nuclear materials via nuclear and/or radiological dispersion devices (dirty bombs) is a serious threat. Therefore, it is crucial to detect proliferation of nuclear material. Critical challenges include: (a) high sensitivity detection of signature emissions from radioactive isotopes, and (b) cost-effectiveness for deployment of sensor networks across large storage facil ...

    STTR Phase II 2019 Department of DefenseDefense Threat Reduction Agency
  10. An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression

    SBC: Norfolk Medical Products, INC.            Topic: NIDDK

    DESCRIPTION provided by applicant The Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetes by transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluid blood ultrafiltrate so that the cells ae protected from immun ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government